Lilly’s Weekly Insulin Candidate Efsitora Alfa Shows Promising Results in Phase III Trials

Eli Lilly's Efsitora Alfa:
Eli Lilly has released positive Phase III data for its once-weekly insulin candidate, efsitora alfa, demonstrating non-inferiority to daily insulin in managing type 1 and type 2 diabetes.

QWINT Trials:
The QWINT-1, QWINT-2, QWINT-3, and QWINT-5 trials have shown that efsitora alfa achieves similar HbA1C reductions compared to daily insulin glargine and insulin degludec in adults with type 1 and type 2 diabetes.

Safety Profile:
The safety and tolerability profile of efsitora alfa is similar to that of daily basal insulin therapies, with comparable or lower rates of severe or clinically significant hypoglycemic events.

Convenience:
Once-weekly insulins like efsitora alfa have the potential to transform diabetes care by making insulin therapy more convenient and reducing its impact on day-to-day lives.

Competitive Advantage:
These results give Lilly a competitive edge over Novo Nordisk, whose once-weekly basal insulin icodec failed to secure FDA approval due to manufacturing and type 1 diabetes use issues.